Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AMG 410 + Panitumumab |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AMG 410 | AMG410|AMG-410 | KRAS G12D Inhibitor 25 KRAS Inhibitor 30 | AMG 410 inhibits KRAS in both GTP- and GDP-bound states, with activity against KRAS G12D, G12V, and G13D, which potentially decreases Kras signaling and tumor growth (Cancer Res (2025) 85 (8_Supplement_2): ND01). | |
| Panitumumab | Vectibix | ABX-EGF | EGFR Antibody 72 | Vectibix (panitumumab) is a monoclonal antibody directed against EGFR, which inhibits cell proliferation and induces apoptosis (PMID: 18998757). Vectibix (panitumumab) is FDA approved for metastatic colorectal cancer patients with wild-type KRAS and NRAS (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07094113 | Phase I | AMG 410 + Panitumumab AMG 410 AMG 410 + Pembrolizumab | AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors | Recruiting | USA | CAN | AUS | 0 |